Fundraising Fox858 Therapeutics, Inc.
San Diego, US · 3 known investors
Find your way into 858 Therapeutics, Inc.
Sign up to see every warm intro you have to 858 Therapeutics, Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the 858 Therapeutics, Inc. team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
858 Therapeutics is a clinical-stage biotechnology company developing targeted cancer therapies that act on tumor dependencies in DNA damage response (DDR) pathways. Its lead program, ETX-19477, is an oral PARG inhibitor being studied in patients with advanced solid tumors.
Founders & leadership
Board
Investors · 3
How we know: a partner's Signal profile · board seat on SEC Form D · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: board seat on SEC Form D · Not right? Tell us
How we know: a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$65.2M disclosed across 3 rounds · 2020–2024
▶$25.2MraisedJul 2024 · 12 investors · PharmaceuticalsRule 506(b)
- James VealExecutive Officer
- Jane HuangDirector
- Monal MehtaDirector
- Stafford JeffreyExecutive Officer, Director
- Ali BehbahaniDirector
- Katherine Bell-McGuinnExecutive Officer
- Clare OzawaDirector
- Offering amount
- $50.4M
- Amount sold
- $25.2M
- First sale
- Jun 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20MraisedMay 2021 · 6 investors · PharmaceuticalsRule 506(b)
- Carlo RizzutoDirector
- Ali BehbahaniDirector
- Jeffrey A. StaffordExecutive Officer, Director
- James VealExecutive Officer
- Clare OzawaDirector
- Offering amount
- $40M
- Amount sold
- $20M
- First sale
- May 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$20.1MraisedMar 2020 · 1 investors · PharmaceuticalsRule 506(b)
- Clare OzawaDirector
- Bradley J. BolzonDirector
- James VealExecutive Officer
- Offering amount
- $37.5M
- Amount sold
- $20.1M
- First sale
- Mar 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does 858 Therapeutics, Inc. do?
- 858 Therapeutics is a clinical-stage biotechnology company developing targeted cancer therapies that act on tumor dependencies in DNA damage response (DDR) pathways. Its lead program, ETX-19477, is an oral PARG inhibitor being studied in patients with advanced solid tumors.
- Who founded 858 Therapeutics, Inc.?
- 858 Therapeutics, Inc. was founded by Stafford Jeffrey.
- Who are 858 Therapeutics, Inc.'s investors?
- 858 Therapeutics, Inc.'s investors include New Enterprise Associates (NEA), Versant Venture Capital, Versant Ventures.
- How much funding has 858 Therapeutics, Inc. raised?
- 858 Therapeutics, Inc. has disclosed $65.2M raised across 3 rounds.
- Where is 858 Therapeutics, Inc. headquartered?
- 858 Therapeutics, Inc. is headquartered in San Diego, US.